Pharmacologic therapy for urticaria

Area of Science:

• Dermatology
• Allergology
• Immunology

Background:

• Chronic urticaria (CU) poses significant challenges in clinical practice and patient management.
• Traditional H1 antagonists, while effective, often cause sedation, leading to the use of newer, non-sedating alternatives.
• Combination therapy with H1 and H2 antagonists shows promise for specific patient groups.

Purpose of the Study:

• To review current and emerging treatment strategies for chronic urticaria.
• To evaluate the efficacy and limitations of various therapeutic options.
• To highlight the need for a deeper understanding of CU pathogenesis.

Main Methods:

• Review of existing literature on chronic urticaria treatments.
• Analysis of traditional H1 antagonists, newer non-sedating H1 antagonists, and combination therapies.
• Evaluation of second-line treatments including corticosteroids, doxepin, dapsone, and others.
• Discussion of potential future therapies like mast cell stabilizers and mediator inhibitors.

Main Results:

• Non-sedating H1 antagonists are increasingly replacing older, sedating versions.
• Combination H1 and H2 antagonist therapy can improve outcomes in select patients.
• Corticosteroids are highly effective for short-term management of severe or recalcitrant chronic urticaria, including specific subtypes like pressure urticaria and urticarial vasculitis.

Conclusions:

• Current treatment paradigms for chronic urticaria are evolving, with a shift towards safer and more targeted therapies.
• While corticosteroids remain crucial for severe exacerbations, their long-term use should be judicious.
• Further research into the pathogenesis of chronic urticaria is essential for developing more rational and effective treatments.